

# Journal of Visualized Experiments

## Presynapse formation assay using presynapse organizer beads and “Neuron ball” culture --Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE59893R1
<b>Full Title:</b>	Presynapse formation assay using presynapse organizer beads and “Neuron ball” culture
<b>Keywords:</b>	Presynapse LRRTM2 local translation Fragile X syndrome FMRP Munc18-1 active zone excitatory synapse
<b>Corresponding Author:</b>	Yukio Sasaki Yokohama Shiritsu Daigaku Yokohama, JAPAN
<b>Corresponding Author's Institution:</b>	Yokohama Shiritsu Daigaku
<b>Corresponding Author E-Mail:</b>	y_sasaki@yokohama-cu.ac.jp
<b>Order of Authors:</b>	Shumaia Parvin Renoma Takeda Yukio Sasaki
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Yokohama, Kanagawa prefecture, Japan

**TITLE:**

Presynapse Formation Assay Using Presynapse Organizer Beads and “Neuron Ball” Culture

**AUTHORS AND AFFILIATIONS:**

Shumaia Parvin<sup>1</sup>, Renoma Takeda<sup>1</sup>, Yukio Sasaki<sup>1</sup>

<sup>1</sup>Functional Structure Biology Laboratory, Department of Medical Life Science, Yokohama City University Graduate School of Medical Life Science, Yokohama, Japan

Corresponding author:

Yukio Sasaki

[y\\_sasaki@yokohama-cu.ac.jp](mailto:y_sasaki@yokohama-cu.ac.jp)

**KEYWORDS:**

presynapse, LRRTM2, local translation, Fragile X syndrome, FMRP, Munc18-1, active zone, excitatory synapse

**SUMMARY:**

Presynapse formation is a dynamic process including accumulation of synaptic proteins in proper order. In this method, presynapse formation is triggered by beads conjugated with a presynapse organizer protein on axonal sheets of “neuron ball” culture, so that accumulation of synaptic proteins is easy to be analyzed during presynapse formation.

**ABSTRACT:**

During neuronal development, synapse formation is an important step to establish neural circuits. To form synapses, synaptic proteins must be supplied in appropriate order by transport from cell bodies and/or local translation in immature synapses. However, it is not fully understood how synaptic proteins accumulate in synapses in proper order. Here, we present a novel method to analyze presynaptic formation by using the combination of neuron ball culture with beads to induce presynapse formation. Neuron balls that is neuronal cell aggregates provide axonal sheets far from cell bodies and dendrites, so that weak fluorescent signals of presynapses can be detected by avoiding overwhelming signals of cell bodies. As beads to trigger presynapse formation, we use beads conjugated with leucine-rich repeat transmembrane neuronal 2 (LRRTM2), an excitatory presynaptic organizer. Using this method, we demonstrated that vesicular glutamate transporter 1 (vGlut1), a synaptic vesicle protein, accumulated in presynapses faster than Munc18-1, an active zone protein. Munc18-1 accumulated translation-dependently in presynapse even after removing cell bodies. This finding indicates the Munc18-1 accumulation by local translation in axons, not transport from cell bodies. In conclusion, this method is suitable to analyze accumulation of synaptic proteins in presynapses and source of synaptic proteins. As neuron ball culture is simple and it is not necessary to use special apparatus, this method could be applicable to other experimental platforms.

**INTRODUCTION:**

Synapse formation is one of critical steps during development of neural circuits<sup>1-3</sup>. Formation of synapses that are specialized compartments composed of pre- and post-synapses is a complex

and multistep process involving appropriate recognition of axons and dendrites, formation of active zone and postsynaptic density, and proper alignment of ion channels and neurotransmitter receptors<sup>1,2</sup>. In each process, many kinds of synaptic proteins accumulate to these specialized compartments in proper timing by transporting synaptic proteins from cell bodies and/or by local translation in the compartments. These synaptic proteins are considered to be arranged in organized manner to form functional synapses. Dysfunction of some synaptic proteins involving synapse formation results in neurological diseases<sup>4,5</sup>. However, it remains unclear how synaptic proteins accumulate in proper timing.

To investigate how synaptic proteins accumulate in organized manner, it is necessary to examine accumulation of synaptic proteins in chronological order. Some reports demonstrated live imaging to observe synapse formation in dissociated culture of neurons<sup>6,7</sup>. However, it is time-consuming to find neurons which just start synapse formation under microscopy. To observe accumulation of synaptic proteins efficiently, synapse formation must start at the time when researchers want to induce the formation. The second challenge is to distinguish accumulation of synaptic proteins due to transport from cell bodies or local translation in synapses. For that purpose, translation level is necessary to be measured under the condition that does not allow transport of synaptic proteins from cell bodies.

We developed novel presynapse formation assay using combination of neuron ball culture with beads to induce presynapse formation<sup>8</sup>. Neuron ball culture is developed to examine axonal phenotype, due to the formation of axonal sheets surrounding cell bodies<sup>9,10</sup>. We used magnetic beads conjugated with leucine-rich repeat transmembrane neuronal 2 (LRRTM2) that is a presynaptic organizer to induce excitatory presynapses (**Figure 1A**)<sup>11–13</sup>. By using the LRRTM2 beads, presynapse formation start at the time when the beads are applied. This means that presynapse formation starts in thousands of axons of a neuron ball at same times, thus it allows to examine precise time course of accumulation of synaptic proteins efficiently. In addition, neuron ball culture is easy to block transport synaptic proteins from soma by removing cell bodies (**Figure 1B**)<sup>8</sup>. We have already confirmed that axons without cell bodies can survive and are healthy at least 4 h after removal of cell bodies. Thus, this protocol is suitable to investigate from where synaptic proteins are derived (cell body or axon), and how synaptic proteins accumulate in organized manner.

## **PROTOCOL:**

The experiments described in this manuscript were performed according to the guidelines outlined in the Institutional Animal Care and Use Committee of the Yokohama City University.

### **1. Preparation of neuron balls as hanging drop culture (Days *in vitro* (DIV) 0-3)**

NOTE: The procedures described here for the preparation of neuron ball culture are based on the method previously reported by the Sasaki group with some modifications<sup>9,10</sup>. We also adopted several procedures from the Banker method for dissociated culture<sup>14</sup>.

#### **1.1. Confirming the followings before starting the dissection**

1.1.1. Prepare all the required solutions and sterilize them by autoclave/filtration in advance.

1.1.2. Keep ready all the instruments and materials to be used in each steps of this cortical neuron culture.

1.1.3. Spray and wipe the laminar air flow cabinet, dissection table, stage plate of stereomicroscope, scissors, and forceps with 70% ethanol.

1.2. Euthanize the mouse upon application of CO<sub>2</sub> and dissect the abdomen to obtain E16 embryos.

1.3. Remove the brains from embryos carefully with the help of fine tips of forceps and transfer them into 60 mm cell culture dishes containing 4 mL of HEPES Buffered Salt Solution (HBSS).

NOTE: The dissection medium HBSS contains 10 mM HEPES (pH 7.4), 140 mM NaCl, 5.4 mM KCl, 1.09 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.1 mM KH<sub>2</sub>PO<sub>4</sub>, 5.6 mM D-glucose, and 5.64 μM phenol red.

1.4. Remove the scalp, cut the olfactory bulb, separate cortices from each cerebral hemisphere using the fine tips of forceps under stereomicroscope, and transfer to another 60 mm dishes containing fresh HBSS. Use at least 3-5 embryos for each separate neuron ball culture.

1.5. Cut the cortices into small pieces with microdissecting spring scissors in a laminar flow cell culture hood.

1.6. Transfer minced cortices to a 15 mL tube and trypsinize the minced cortices in 4 mL of 0.125% trypsin in HBSS for 4.5 min in a water bath at 37 °C.

NOTE: This trypsinization time is critical for efficient neuron culture as the increasing time (> 4.5 min) leads to much more dead neurons.

1.7. Transfer the cell aggregates to a new 15 mL tube containing 10 mL of HBSS by a sterile transfer pipette, and incubate at 37 °C for 5 min. Repeat this step one more time.

1.8. Transfer the cell aggregates to a new 15 mL tube containing 2 mL of Neurobasal media containing GlutaMax, B27 supplement (NGB medium), 0.01% DNase I and 10% horse serum.

1.9. Triturate the trypsinized cortices by repeatedly pipetting them up and down (3-5 times) using fire-polished fine glass Pasteur pipette.

NOTE: Diameter of fire-polished fine glass Pasteur pipette is very important as described in the Banker method paper<sup>14</sup>. If the pipette is too narrow to pass cortices, prepare pipettes possessing 2-3 different sizes, and try from larger pipette.

1.10. For preparing neuron balls, take the above cell suspension and adjust the cell density to  $1 \times 10^6$  cells/mL using NGB medium.

1.11. Culture the cortical neurons as hanging drops containing 10,000 cells/drop (1 drop is 10  $\mu$ L) inside the upper lids of 10 cm culture dishes.

1.12. Add 7 mL of phosphate buffered saline (PBS) to the bottom part of culture dishes, then keep in an incubator for 3 days at 37 °C with 5% CO<sub>2</sub> under humidified condition to allow for neuron ball formation.

## **2. Placing neuron balls on PLL-coated glass coverslips and culture maintenance (DIV 3-11)**

NOTE: Before coating of glass coverslips with poly-L-lysine (PLL), washing the coverslips using detergent is important. Glass coverslips are sometimes not so clean for neuronal culture and uniform coating with PLL. Non-uniform PLL coating may result in uneven axonal extension of neuron balls.

2.1. Soak the coverslips in 1/20 diluted neutral non-phosphorous detergent in ceramic racks for 1-3 overnights.

2.2. Wash the coverslips 8 times in ultrapure water, and then sterilize in an oven at 200 °C for 12 h.

NOTE: All the steps from here must be done in a laminar air flow cell culture hood.

2.3. Transfer baked coverslips to 100-mm dishes. After sealing the dish by parafilm between a lid and a bottom dish, baked coverslips can be kept for long-term storage.

2.4. (Optional) Apply paraffin dots to the coverslips. The dots make space to prevent neuron balls detaching from the coverslips during immunostaining by direct contact of neuron balls to plastic dishes. Melt paraffin in a suitable bottle in a hot water bath at about 90 °C. Dip a Pasteur pipette into the paraffin, then rapidly touch it to make three spots near the edge of a coverslip.

2.5. Coat PLL (MW > 300,000) onto the paraffin-beaded glass coverslips in 60-mm dishes using PLL solution (15  $\mu$ g/mL in borate buffer), and keep them for at least 1 h in a CO<sub>2</sub> incubator.

2.6. After washing 4 times with PBS, transfer the PLL-coated coverslips to a 4-well plate containing 350  $\mu$ L of NGB medium in each well and cytosine  $\beta$ -D-arabinofuranoside hydrochloride (AraC, 3  $\mu$ M) to the media to kill dividing cells.

2.7. Keep this 4-well plate containing the PLL-coated coverslips in the CO<sub>2</sub> incubator at least for 20 min to ensure the temperature of the medium reach 37 °C before transferring neuron balls.

2.8. At DIV 3 when “neuron balls” are formed very well, transfer them onto PLL-coated coverslips inside the 4-well plate (5 neuron balls/well) kept in the CO<sub>2</sub> incubator.

2.9. After 48 h, replace the neuron ball culture medium with fresh AraC-free NGB medium. Use a hot plate in a laminar air flow cell culture hood whose temperature is kept ready at 37 °C immediately before this procedure.

NOTE: It is necessary to perform the medium changing as rapidly as possible on a hot plate to reduce the time that the cultures are at the outside of the CO<sub>2</sub> incubator.

2.10. Keep this neuron ball culture in the CO<sub>2</sub> incubator for up to DIV 11.

NOTE: At DIV 11-12, neuron balls extending neurites up to 1-2 mm are used for experiments.

### **3. Applying LRRTM2 beads on neuron ball culture with or without cell bodies (DIV 11-12)**

NOTE: Before application of LRRTM2 beads on neuron ball culture, it is recommended to remove cell bodies. Therefore, prepare LRRTM2 beads at first, then remove the cell bodies and later apply LRRTM2 beads to culture as early as possible. Biotinylated LRRTM2 is provided by the Nogi's group (Yokohama City University) as conditioned medium. They use an expression vector including biotin acceptor sequence and biotin ligase from *E. coli* (BirA)<sup>15,16</sup> to attach biotin to LRRTM2, and the expression vector is transfected to Expi293F cells included in the Expi293 Expression System. The vector information is available in **Supplementary Figure 1**. Biotinylated LRRTM2-conjugated streptavidin beads reduced background of immunostaining greatly compared to LRRTM2-Fc –conjugated Protein A beads that are used for prototype LRRTM2 system<sup>8</sup>.

#### **3.1. Preparation of biotinylated LRRTM2 beads**

3.1.1. To remove excess biotin from conditioned medium of Expi293F cells expressing biotinylated LRRTM2, apply 1.7 mL of the conditioned medium mixed with 0.8 mL of PBS (total 2.5 mL) to PD-10 gel filtration column. PD-10 column is pre-equilibrated with 25 mL of ultrapure water and 25 mL of PBS.

3.1.2. Elute with 3.5 mL of PBS and collect the flow-through as a LRRTM2 stock.

NOTE: This LRRTM2 stock can be dispensed to aliquots and stored at -80 °C for long-term. Expression levels of biotinylated LRRTM2 sometimes vary from lot to lot. Thus, proper volume of LRRTM2 stock to conjugate to the beads should be determined to form presynapses enough on neuron balls, when new lot of LRRTM2 stock is used at first time.

3.1.3. Take 20 µL from the suspension of streptavidin-coated magnetic particles (diameter: 4-5 µm) to a microcentrifuge tube. Immobilize the beads to a handmade apparatus attached with

neodymium permanent magnets and wash three times with 100  $\mu$ L of PBS-MCBC in 1.5 mL microcentrifuge tubes.

NOTE: PBS-MCBC contains PBS including 5 mM  $MgCl_2$ , 3 mM  $CaCl_2$ , 0.1% BSA, and 0.1% Complete EDTA-free.

3.1.4. After removing completely PBS-MCBC from the beads, add predetermined volume of LRRTM2 stock (usually 500-1,000  $\mu$ L, see Note 3.1.2) to the washed beads. Incubate the mixture using rotator at 4  $^{\circ}$ C for 1-2 h.

3.1.5. Wash the beads twice with 100  $\mu$ L of PBS-MCBC, and later with 100  $\mu$ L of NGB medium.

3.1.6. Resuspend the LRRTM2 beads in 50  $\mu$ L of NGB medium for application to the neuron ball culture.

3.1.7. Use same procedures for preparing the control beads (negative control) in another microcentrifuge tube except adding biotinylated-LRRTM2 proteins.

### **3.2. Removing cell bodies from neuron balls at DIV 11-12 and applying LRRTM2 beads**

3.2.1. Label the wells of a 4-well plate as “Cell body (+)” and “Cell body (-)”.

3.2.2. Cut the ending of a yellow tip at 45 $^{\circ}$  angle with a razor blade previously sprayed with 70% ethanol under stereomicroscope (**Figure 1B**).

3.2.3. Put the yellow tip end on the cell body area of a neuron ball and remove the cell bodies by suction (**Figure 1B**).

3.2.4. To identify each specified condition of the experiment, label the wells again as “LRRTM2 beads” and “Control beads”.

3.2.5. Apply the LRRTM2 and control beads on neuron ball culture, and submerge to the bottom of the plates for 1 min using ferrite magnets to start presynapse formation. This procedure ensures to touchdown all beads at the same time. Especially, it would be effective for short time incubation (e.g., 30 min and 1 h) with LRRTM2 beads synchronously.

3.2.6. To perform time-course experiments, label each separate well as 0 min, 30 min, 1 h, 2 h, 4 h and 18 h and apply LRRTM2 beads at the indicated time intervals.

3.2.7. After the addition of LRRTM2 beads, incubate the neuron ball culture with the beads for specified time (0 min to 18 h) to form presynapses.

## **4. Immunostaining and microscopy**

NOTE: Fix the cells for 4 h via incubation with LRRTM2 beads in the experimental conditions with and without cell bodies, as the axons tend gradually to die in absence of cell bodies after 4 h. In case of time course with LRRTM2 beads, fix the cells at the indicated specified time.

#### **4.1. Fixing and staining neurons in neuron ball culture after presynapse formation with LRRTM2 beads**

4.1.1. Remove NGB medium and fix the neuron balls with 4% PFA in PBS (250  $\mu$ L/well) for 20 min at room temperature, and then wash with 500  $\mu$ L of PBS 4-times each 5 min.

4.1.2. Wash the fixed cells with TBS (Tris-buffered saline: 50 mM Tris-HCl (pH 7.3) and 150 mM NaCl) for more than 5 min.

4.1.3. Permeabilize the cells/axons of neuron ball culture with TBS containing 0.3% Triton X-100 for 5 min.

4.1.4. Keep the cells 1 h for blocking with blocking buffer (0.1% Triton X-100 and 5% NGS (normal goat serum) in TBS).

4.1.5. Incubate the cells with primary antibodies; anti-rabbit-vGlut1 (vesicular glutamate transporter 1 (1:4000)) and anti-mouse-Munc18-1 (1:300) diluted with antibody diluent for overnight at 4 °C.

4.1.6. Wash the coverslips 4 times with immunofluorescence (IF) buffer (0.1% Triton X-100 and 2% BSA in TBS) and incubate for 30 min with fluorophore (Alexa dye)-conjugated 2nd antibodies; anti-mouse-IgG-Alexa 555 (1:500), anti-rabbit-IgG-Alexa 488 (1:1000).

4.1.7. Stain the nuclei of the cell bodies of neurons for 5 min with 4',6-diamidino-2-phenylindole (DAPI, 1  $\mu$ g/mL) in PBS.

4.1.8. Wash the coverslips three times with PBS and then mount on glass slides using mounting media containing 167 mg/mL poly (vinyl) alcohol and 6 mg/mL N-propyl gallate.

4.1.9. Store the glass slides in a refrigerator at -20 °C until microscopy. Fluorescent signals of the glass slides are detectable for at least 1 year when the slides are stored at -20 °C.

#### **4.2. Taking images under fluorescence microscope**

4.2.1. Capture phase and IF images under an inverted fluorescent microscope with a cooled CCD camera using 60X oil immersion lens. For image acquisition software, use a software installed microscope system. Use Image J as image analysis software.

4.2.2. Measure the IF intensity in presynapses in axon using following formula; IF intensities of Region of Interest on beads (ROI) – Off beads region intensity/Axonal intensity along 20  $\mu$ m from



beads – background intensity. This ratio intensity provides protein accumulation index (**Figure 4A**). Accomplish the measurements on original 16-bit images using Image J software.

4.2.3. To quantify the accumulation level of particular protein in presynapse induced with LRRTM2 beads, always select the area away from 2-field of view or more apart from the cell body with microscope (60X).

NOTE: The selection of area in neuron ball for imaging is crucial as dense axons are near the cell body and periphery of neuron ball can provide single axon.

4.2.4. For accurate measurement, choose 5-different axonal field (similar distance from cell bodies)/coverslip.

4.2.5. Keep identical imaging conditions at different day and in between experiments

#### **REPRESENTATIVE RESULTS:**

Here, we show representative results of accumulation of presynaptic proteins in LRRTM2-induced presynapses of axonal sheets of neuron ball culture. As presynaptic proteins, we analyzed the excitatory synaptic vesicle protein vGlut1 and the active zone protein Munc18-1. We also examined time course of accumulation of vGlut1 and Munc18-1 in presynapses, and obtained results indicating source of Munc18-1 in presynapses using axons removing cell bodies and a protein synthesis inhibitor. Recently, we have investigated a role of Fragile X mental retardation protein (FMRP) on accumulation of Munc18-1 in presynapses<sup>8</sup>. FMRP, which is a causative gene product of Fragile X syndrome (FXS), is a mRNA binding protein to suppress translation<sup>17–19</sup>. We also examined the involvement of FMRP in the Munc18-1 accumulation using FXS model mice which is deficient in *Fmr1* gene encoding FMRP.

Application of LRRTM2-beads into neuron ball culture at DIV11 induced accumulation of Munc18-1 in presynapses of axons of neuron balls (**Figure 2A**). Even in axons which are removed cell bodies, accumulation of Munc18-1 was observed under the beads similar as axons of neuron balls with cell bodies (**Figure 2B**). In typical case, over 80% of beads after 4 h-incubation with neuron balls can induce accumulation of synaptic proteins in presynapses, judged by staining Munc18-1 and vGlut-1. Because axons are so crowded and overlapped near cell bodies (**Figure 2Aa, Ba**), more peripheral region of axonal sheets were measured where axons are not so overlapped (**Figure 2Ab, Bb**, e.g., peripheral area away from 2-field of view or more apart from the cell body with microscope (60X)). When peripheral region of axonal sheet was analyzed by high-magnification objective lens (60X), vGlut1 and Munc18-1 accumulated clearly in presynapses of axons under the beads (**Figure 3**). Sometimes, fluorescent signals of synaptic vesicular proteins like vGlut1 are hard to be detected in axonal region outside the beads, because these synaptic vesicular proteins accumulate so much under the beads. In the case of Munc18-1, fluorescent signals can be detected weakly in axonal region outside the beads.

To quantify accumulation level of synaptic proteins in presynapses induced by LRRTM2-beads, fluorescent intensities of axons under the beads and outside the beads were measured, and then

calculated as “Protein accumulation index” (**Figure 4A**, and described in protocol section in detail). Time course experiments demonstrated that accumulation of vGlut1 in presynapses increased significantly at 30 min (**Figure 4B**). On the other hand, Munc18-1 accumulation started to increase significantly at 2 h, and reach a plateau at 4 h (**Figure 4C**). These data indicate that the synaptic vesicle protein vGlut1 accumulates in presynapses earlier than the active zone protein Munc18-1. The Munc18-1 accumulation in presynapses of *Fmr1*-KO neurons increased 1.5 times more than those in wild type (WT) (**Figure 4C**), indicating involvement of FMRP in Munc18-1 accumulation. Next, to distinguish the Munc18-1 accumulation due to transport from cell bodies or local translation in axons, an effect of the protein synthesis inhibitor anisomycin were examined on the accumulation in the presence or absence of cell bodies (**Figure 4D**). Anisomycin suppressed the Munc18-1 accumulation significantly in axons (**Figure 4D**), indicating that the accumulation is protein synthesis-dependent. The accumulation in presynapses of axons without cell bodies was not significantly different to that with cell bodies (**Figure 4D**). These results suggest that accumulation of Munc18-1 in presynapses are derived mostly from axons, but not transport of Munc18-1 from cell bodies. If accumulation of synaptic proteins is suppressed in presynapses of axons by removing cell bodies, it is considered that this decrease is due to transport from cell bodies. Actually, when we examined the accumulation of total newly synthesized proteins metabolically labeled by fluorescent dye, removing cell bodies reduced significantly the accumulation of total newly synthesized proteins, compared to presynapses of axons with cell bodies<sup>8</sup>. Although the Munc18-1 accumulation in *Fmr1*-KO increased more compared to WT, anisomycin suppressed the accumulation in similar level to WT and removing cell bodies had no effect on the accumulation (**Figure 4D**). These results suggest that FMRP is involved in local translation of Munc18-1 in axons.

Representative results presented here demonstrate that this method is suitable to investigate how synaptic proteins accumulate in organized manner by time course experiments, and to examine source of synaptic proteins (transport from cell bodies or local translation in axons) by removing cell bodies.

#### FIGURE AND TABLE LEGENDS:

**Figure 1. Scheme of presynapse formation and removal of cell bodies from neuron ball. (A)** Presynapse formation assay using biotinylated LRRTM2 conjugated streptavidin beads to induce the presynapses in axons of neuron ball culture prepared from E16 cortices. LRRTM2, a postsynaptic protein, binds neuroligin (NRXN) and act as a presynapse organizer. Streptavidin beads conjugated to biotinylated LRRTM2 extracellular regions (LRRTM2 beads) were applied at DIV11-12 to neuron ball culture to induce presynapses. This figure has been modified from previous publication<sup>8</sup>. **(B)** The yellow tip end was cut and placed on the cell body area of neuron ball culture at 45° angle. The cell bodies were removed by suction.

**Figure 2. Munc18-1 accumulation in presynapses in presence and absence of cell bodies of neuron ball. (A)** After 4 h incubation with LRRTM2 beads, the active zone protein Munc18-1 accumulated at the induced presynaptic sites in axons (Upper panel; experimental scheme, middle; phase image, lower; IF images of Munc18-1 accumulation). Images were captured as low magnification images using 10X lens and intermediate magnification (1.5X) to see the whole

picture composed of a neuron ball, axons, and beads. Dashed squares indicate the area of neuron ball for accurate imaging position of beads. Scale bar, 20  $\mu\text{m}$  (left; original image), 10  $\mu\text{m}$  (right; enlarged image). **(B)** Munc18-1 accumulated very well even in the absence of cell bodies at the induced presynaptic sites in axons. This result indicates that axons can survive and form presynapses even after removing cell bodies for at least 4 h.

**Figure 3. Accumulation of vGlut1 and Munc18-1 in presynapses of axons with and without cell bodies.** The excitatory presynaptic marker vGlut1 (green) and Munc18-1 (Red) accumulated in presynapses 4 h after addition of LRRTM2 beads. (Upper panel; with cell bodies, lower; without cell bodies). Images were captured using 60X oil immersion lens for high magnification to measure fluorescent intensity. Dashed circle outlined the position of beads. Munc18-1 accumulated almost similar extent in presence and absence of cell bodies in presynapses but vGlut1 accumulation is reduced without cell bodies<sup>8</sup>. Scale bar, 5  $\mu\text{m}$ .

**Figure 4. Procedure of IF intensity measurement and impact of cell bodies removal and protein synthesis inhibitor on Munc18-1 accumulation in neuron balls.** **(A)** Diagram showed the quantification method of IF intensity at an induced-presynaptic site in axon of neuron ball culture. Scale bar, 5  $\mu\text{m}$ . The details are described in protocol section. **(B)** Time course of vGlut1 accumulation in presynapses induced with LRRTM2 beads. Data shown are mean  $\pm$  SEM for  $n = 20$ . Two-way ANOVA with Tukey's multiple comparison test.  $**p < 0.01$ . **(C)** Time course of Munc18-1 accumulation in WT and *Fmr1*-KO presynapses under LRRTM2 beads. Data shown are mean  $\pm$  SEM for  $n = 20$ , Two-way ANOVA with Tukey's multiple comparison test. n.s., not significant;  $**p < 0.01$ , significantly different between WT and KO. **(D)** The bar graph showed Munc18-1 accumulation level in presynapses of WT and *Fmr1*-KO neuron balls in the presence or absence of 25  $\mu\text{M}$  anisomycin (Aniso) with (CB+) or without (CB-) cell bodies. Data shown are mean  $\pm$  SEM for  $n = 20$ . Two-way ANOVA with Tukey's multiple comparison test.  $**p < 0.01$ , n.s., not significant. # indicated  $p < 0.01$ , significantly different with and without anisomycin. These figures have been modified from previous publication<sup>8</sup>.

**Supplementary Figure 1. Bicystronic expression vector for LRRTM2-ECR (Extracellular Region) and BirA (biotin ligase from *E. coli*).** Between LRRTM2-ECR and BirA coding sequences, there is an Internal Ribosomal Entry Site (IRES) sequence that allows to co-express both proteins from single mRNA. hEF1-HTLV promoter drives expression the bicystronic mRNA, and both proteins are secreted by signal peptide sequences after translation. LRRTM2-ECR coding sequence is attached to several peptide tag sequences (DYKDDDDK, TEV, Myc and His tags) and Biotin Acceptor Sequence (BAS). BirA is attached to DYKDDDDV tag. Secreted BirA biotinylates lysine of BAS sequence of LRRTM2-ECR to bind to streptavidine beads.

## DISCUSSION:

We developed novel method to examine presynapse formation stimulated with LRRTM2-beads using neuron ball culture. Currently, most of presynapse formation assay includes poly-D-lysine (PDL)-coated beads and dissociated culture/microfluidic chamber<sup>20-22</sup>. One of advantages of this method is LRRTM2-beads. While LRRTM2 interacts with neuroligin to form excitatory presynapses specifically<sup>11-13</sup>, PDL-beads induces both excitatory and inhibitory presynapses nonspecifically<sup>20</sup>.

In this method, other presynapse organizers, whose members are over 10 proteins<sup>3</sup>, are applicable to induce presynapses by changing extracellular domain of biotinylated protein depending on experimental purpose.

Another advantage is neuron ball culture. In some cases, conventional dissociated culture was used to analyze presynapse formation<sup>20</sup>. However, dissociated culture is not suitable to analyze low levels of synaptic proteins within presynapses, because overwhelming signals in cell bodies and dendrites interfere signals in presynapses. Instead, some groups use dissociated culture in microfluidic chamber that is special apparatus to culture axons and cell bodies separately in 2 compartments<sup>21,22</sup>. Using microfluidic chamber, axonal sheet is formed in axonal compartment, and cell bodies are able to be removed from cell body compartment, similar to neuron ball culture. However, microfluidic chamber is special apparatus, and requires some skills to maintain constant culture condition. Neuron ball culture is not necessary to use special apparatus, and is relatively easy to be introduced as a new experimental method. Because essence of neuron ball culture is just to place neuronal cell aggregates (neuron balls) to glass-bottom dish/chamber, it can be easily combined with other methods. For example, it is considered that neuron ball culture using LRRTM2-beads is applicable for high content screening to measure fluorescence of 10-20 beads area at same time.

Critical step of this protocol is coating with PLL. If PLL coating is not uniform, axons of neuron balls would not extend uniformly in all direction. This disturbs efficient analysis of presynapse formation. We use glass coverslips and glass-bottom dishes, however, glass is sometimes not so clean for neuronal culture and uniform coating with PLL. In this protocol, at first, glass coverslips and glass-bottom dishes are soaked in neutral non-phosphorous detergent for 1-3 overnight, and then washed 8 times with ultrapure water. We use PLL whose molecular weight > 300,000 to reduce its concentration (15 µg/mL) for lower undesirable background. If lower molecular weight of PLL (*e.g.*, 30,000-70,000) is used, higher concentration (100 µg/mL) is necessary to extend axons.

Limitation of this method is that neuron ball culture cannot maintain > DIV15-16. Axons of neuron balls are fragmented after DIV15-16. Fragmented axons do not produce any presynapse after LRRTM2 beads application. Thus, this method is not applicable to analyze mature neurons (> DIV21). However, in most cases<sup>11, 12, 21, 22</sup>, presynapse formation assay uses younger neurons that are cultured until DIV14. Another limitation is that axons without cell bodies cannot survive over 4 h. We analyzed accumulation of 5 synaptic proteins in presynapses so far, the accumulation of all proteins we checked reached almost plateau within 4 h (unpublished observation). It is considered that synaptic proteins accumulate enough at 4 h to analyze where synaptic proteins are derived from (cell body or axon).

Combination of neuron ball culture with LRRTM2-beads is relatively simple and flexible to adapt many experimental platforms. We have already applied this method to measure presynaptic activity using AM1-43 dye (unpublished observation). This method is considered to be applicable for high throughput screening. Presynapse formation assay is possible to apply high content screening by staining synaptic proteins in presynapses formed under LRRTM2-beads. This

method would contribute to find new compounds to cure neurological disease.

#### ACKNOWLEDGMENTS:

This work is partly supported by JSPS Grant-in-Aid for Scientific Research (KAKENHI) (C) (No. 22500336, 25430068, 16K07061) (Y. Sasaki). We thank Dr. Terukazu Nogi and Ms. Makiko Neyazaki (Yokohama City University) for kindly providing biotinylated LRRTM2 protein. We also thank Honami Uechi and Rie Ishii for technical assistance.

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES:

1. Waites, C.L., Craig, A.M., Garner, C.C. Mechanisms of Vertebrate Synaptogenesis. *Annual Review of Neuroscience*. **28** (1), 251–274, doi: 10.1146/annurev.neuro.27.070203.144336 (2005).
2. Ziv, N.E., Garner, C.C. Cellular and molecular mechanisms of presynaptic assembly. *Nature Reviews Neuroscience*. **5** (5), 385–399, doi: 10.1038/nrn1370 (2004).
3. Chia, P.H., Li, P., Shen, K. Cellular and molecular mechanisms underlying presynapse formation. *Journal of Cell Biology*. **203** (1), 11–22, doi: 10.1083/jcb.201307020 (2013).
4. Südhof, T.C. Neuroligins and neurexins link synaptic function to cognitive disease. *Nature*. **455** (7215), 903–911, doi: 10.1038/nature07456 (2008).
5. Saitsu, H. *et al.* CASK aberrations in male patients with Ohtahara syndrome and cerebellar hypoplasia. *Epilepsia*. **53** (8), 1441–9, doi: 10.1111/j.1528-1167.2012.03548.x (2012).
6. Friedman, H.V., Bresler, T., Garner, C.C., Ziv, N.E. Assembly of New Individual Excitatory Synapses. *Neuron*. **27** (1), 57–69, doi: 10.1016/S0896-6273(00)00009-X (2000).
7. Bresler, T. *et al.* Postsynaptic density assembly is fundamentally different from presynaptic active zone assembly. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. **24** (6), 1507–20, doi: 10.1523/JNEUROSCI.3819-03.2004 (2004).
8. Parvin, S., Takeda, R., Sugiura, Y., Neyazaki, M., Nogi, T., Sasaki, Y. Fragile X mental retardation protein regulates accumulation of the active zone protein Munc18-1 in presynapses via local translation in axons during synaptogenesis. *Neuroscience Research*. doi: 10.1016/j.neures.2018.09.013 (2018).
9. Sasaki, Y. *et al.* Phosphorylation of Zipcode Binding Protein 1 Is Required for Brain-Derived Neurotrophic Factor Signaling of Local  $\beta$ -Actin Synthesis and Growth Cone Turning. *Journal of Neuroscience*. **30** (28), 9349–9358, doi: 10.1523/JNEUROSCI.0499-10.2010 (2010).
10. Sasaki, Y., Gross, C., Xing, L., Goshima, Y., Bassell, G.J. Identification of axon-enriched microRNAs localized to growth cones of cortical neurons. *Developmental neurobiology*. **74** (3), 397–406, doi: 10.1002/dneu.22113 (2014).
11. Linhoff, M.W. *et al.* An Unbiased Expression Screen for Synaptogenic Proteins Identifies the LRRTM Protein Family as Synaptic Organizers. *Neuron*. **61** (5), 734–749, doi: 10.1016/j.neuron.2009.01.017 (2009).
12. de Wit, J. *et al.* LRRTM2 Interacts with Neurexin1 and Regulates Excitatory Synapse

- Formation. *Neuron*. **64** (6), 799–806, doi: 10.1016/j.neuron.2009.12.019 (2009).
13. Ko, J., Fuccillo, M. V., Malenka, R.C., Südhof, T.C. LRRTM2 Functions as a Neurexin Ligand in Promoting Excitatory Synapse Formation. *Neuron*. **64** (6), 791–798, doi: 10.1016/j.neuron.2009.12.012 (2009).
14. Kaech, S., Banker, G. Culturing hippocampal neurons. *Nature protocols*. **1** (5), 2406–15, doi: 10.1038/nprot.2006.356 (2006).
15. Hirai, H. *et al.* Structural basis for ligand capture and release by the endocytic receptor ApoER2. *EMBO reports*. doi: 10.15252/embr.201643521 (2017).
16. Yasui, N. *et al.* Functional Importance of Covalent Homodimer of Reelin Protein Linked via Its Central Region. *Journal of Biological Chemistry*. **286** (40), 35247–35256, doi: 10.1074/jbc.M111.242719 (2011).
17. Bassell, G.J., Warren, S.T. Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function. *Neuron*. **60** (2), 201–214, doi: 10.1016/j.neuron.2008.10.004 (2008).
18. Darnell, J.C., Klann, E. The translation of translational control by FMRP: therapeutic targets for FXS. *Nat Neurosci*. **16** (11), 1530–1536, doi: 10.1038/nn.3379 (2013).
19. Richter, J.D., Bassell, G.J., Klann, E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. *Nature Reviews Neuroscience*. **16** (10), 595–605, doi: 10.1038/nrn4001 (2015).
20. Lucido, A.L. and Rapid Assembly of Functional Presynaptic Boutons Triggered by Adhesive Contacts. *Journal of Neuroscience*. **29** (40), 12449–12466, doi: 10.1523/JNEUROSCI.1381-09.2009 (2009).
21. Taylor, A.M., Wu, J., Tai, H.-C., Schuman, E.M. Axonal Translation of  $\beta$ -Catenin Regulates Synaptic Vesicle Dynamics. *Journal of Neuroscience*. **33** (13), 5584–5589, doi: 10.1523/JNEUROSCI.2944-12.2013 (2013).
22. Batista, A.F.R., Martínez, J.C., Hengst, U. Intra-axonal Synthesis of SNAP25 Is Required for the Formation of Presynaptic Terminals. *Cell reports*. **20** (13), 3085–3098, doi: 10.1016/j.celrep.2017.08.097 (2017).

Figure 1.





Figure 2.







**Figure 3.**

Figure 4.



Name of Material/ Equipment	Product name	Company	Catalog Number	Comments/Description
	Antibody diluent	DAKO	S2022	
	Alexa Fluor 594 AffiniPure Donkey Anti-Mouse IgG (H+L)	Jackson ImmunoResearch	715-585-151	
	Alexa Fluor 488 AffiniPure Donkey Anti-Rabbit IgG (H+L)	Jackson ImmunoResearch	711-545-152	
	mouse anti-Munc18-1	BD Biosciences	610336	
	B-27 Supplement (50X), serum free	Thermo Fisher Scientific	17504044	
	Bovine Serum Albumin (BSA)	Nacalai Tesque	01863-48	
	Cell-Culture Treated Multidishes (4 well dish)	Nunc	176740	
	Complete EDTA-free	Roche	11873580001	
	cooled CCD camera	Andor Technology	IXON3	
	Coverslip	Matsunami	C015001	Size: 15 mm, Thickness: 0.13-0.17 mm
	Cytosine $\beta$ -D-arabinofuranoside (AraC)	Sigma-Aldrich	C1768	
	4',6-Diamidino-2-phenylindole Dihydrochloride (DAPI)	Nacalai Tesque	11034-56	
	Deoxyribonuclease 1 (DNase I)	Wako pure chemicals	047-26771	
	Expi293 Expression System	Thermo Fisher Scientific	A14635	
	Horse serum	Sigma-Aldrich	H1270	
	image acquisition software	Nikon	NIS-element AR	
	Image analysis software	NIH	Image J	<a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a>
	Inverted fluorescent microscope	Nikon	Eclipse Ti-E	
	GlutaMAX	Thermo Fisher Scientific	35050061	
	Neurobasal media	Thermo Fisher Scientific	#21103-049	
	Normal Goat Serum (NGS)	Thermo Fisher Scientific	#143-06561	
	N-propyl gallate	Nacalai Tesque	29303-92	
	Paraformaldehyde (PFA)	Nacalai Tesque	26126-25	
	Paraplast Plus	Sigma-Aldrich	P3558	
	Poly-L-lysine Hydrobromide (MW > 300,000)	Nacalai Tesque	28359-54	
	poly (vinyl alcohol)	Sigma	P8136	
	Prepacked Disposable PD-10 Columns	GE healthcare	17085101	
	rabbit anti-vesicular glutamate transporter 1	Synaptic Systems	135-302	
	SCAT 20X-N (neutral non-phosphorous detergent)	Nacalai Tesque	41506-04	
	Streptavidin-coated magnetic particles	Spherotech Inc	SVM-40-10	diameter: 4-5 $\mu$ m
	TritonX-100	Nacalai Tesque	35501-15	
	Trypsin	Nacalai Tesque	18172-94	



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
[www.jove.com](http://www.jove.com)

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Presynapse formation assay using presynapse organizer beads and "Neuron ball" culture

Author(s):

Shumaia Parvin, Renoma Takeda, Yukio Sasaki

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	Yukio Sasaki	
Department:	Department of Medical Life Science	
Institution:	Yokohama City University Graduate School of Medical Life Science	
Title:	Ph.D.	
Signature:		Date: Feb 25th, 2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

April 5th, 2019

Journal of Visualized Experiments (JoVE)

Dear Editors,

Thank you very much for your mail of March 19th concerning our manuscript (Ref: JoVE59893) entitled "Presynapse formation assay using presynapse organizer beads and "Neuron ball" culture" together with the reviewers' comments. We are pleased to learn that you are interested in our paper for publication in Journal of Visualized Experiments (JoVE).

We have carefully examined the editorial and reviewers' comments and will now respond to each of the comments in turn, indicating revisions made to the text as appropriate.

**- Editorial comments:**

*1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.*

We have checked proofread our manuscript thoroughly.

*2. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."*

We obtained copyright permission from Neuroscience Research (Publisher: Elsevier) by Elsevier and Copyright Clearance Center. Original "Elsevier and Copyright Clearance Center" document is pdf, however, I attached docx version according to the Editor's suggestion. We have cited Figures like this: "This figure has been modified from<sup>8</sup>".

*3. Please use 12 pt font and single-spaced text throughout the manuscript.*

We have used 12 pt Calibri font. We have changed single-spaced text throughout the manuscript.

*4. Please adjust the numbering of the Protocol to follow the JoVE Instructions for Authors. For example, 1 should be followed by 1.1 and then 1.1.1 and 1.1.2 if necessary. Please refrain from using bullets or dashes.*

We checked the numbering of the protocol.

*5. Please add a one-line space between each of your protocol steps.*

We added a one-line space between protocol steps.

*6. JoVE cannot publish manuscripts containing commercial language. This includes company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.*

We have removed company names from our protocol. For example, We changed “MilliQ water” and “SCAT 20X-N” to “ultrapure water” and neutral non-phosphorous detergent, respectively.

*7. Please use standard SI unit symbols and prefixes such as  $\mu\text{L}$ , mL, L, g, m, etc.*

We changed “ml” to mL”

*8. Please use h, min, s for time units.*

We changed “hr” to “h”.

*9. There is a 2.75 page limit for filmable content. Please highlight 2.75 pages or less of the Protocol steps (including headings and spacing) in yellow that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.*

We highlight essential steps in yellow within 2.75 pages.

**Reviewers' comments:**



**Reviewer #1:**

Manuscript Summary:

*The MS reported by Parvin et al. describes the sophisticated method that makes possible to observe synapse formation easily in vitro. The protocol is well explained.*

We thank reviewer #1 for highly appreciating our protocol.

Minor Concerns:

*The only concern is, (although it is not directly related to the method) the lack of the sequence and vector information of LRRTM2 expression system. To reproduce the experiment, it is necessary to be described in detail.*

We have added the vector information as a supplementary figure 1. We also added figure legend for supplementary figure 1 in FIGURE AND TABLE LEGENDS section.

**Reviewer #2:**

Manuscript Summary:

*The authors describe a method for studying presynapse formation by combining pseudo-explant or neuron ball cultures with the axonal application of LRRTM2 coated beads. The methods allows for the removal of the cell bodies and the study of local protein synthesis without the use of microfluidic chambers.*

We also thank reviewer 2 for highly appreciating our protocol.

Major Concerns:

*p.4 line 89: most of the solutions should not be autoclaved as they contain serum, glucose, etc.*

*Major copy-editing is needed.*

We understand autoclave is not allowed to sterilize some solutions, because serum and some reagent is vulnerable to high temperature. For heat vulnerable solution, we used filtration for sterilization. We changed the old version of sentence "Prepare and autoclave all the required solutions in advance" to "Prepare all the required solutions and sterilize them by autoclave/filtration in advance" (line 89).

We also checked spelling and typo errors in our manuscript. We hope that you will find these changes satisfactory and the revised version is now acceptable for publication in *JoVE*. We wish to thank you again for your thorough and prompt review of our manuscript and to thank the reviewers for their constructive and useful criticisms and suggestions.

Sincerely,

A handwritten signature in black ink, appearing to read 'Y. Sasaki'.

Yukio Sasaki, Ph.D.

Associate professor


Department of Medical Life Science

Yokohama City University Graduate School of Medical Life Science

Yokohama 230-0045, Japan.



Supplementary Fig. 1



Rightslink® by Copyright Clearance Center

Title: Fragile X mental retardation protein regulates accumulation of the active zone protein Munc18-1 in presynapses via local translation in axons during synaptogenesis

Author: Shumaia Parvin, Renoma Takeda, Yu Sugiura, Makiko Neyazaki, Terukazu Nogi, Yukio Sasaki

Publication: Neuroscience Research

Publisher: Elsevier

Date: Available online 19 September 2018

© 2018 Elsevier B.V. and Japan Neuroscience Society.

All rights reserved.

Order Completed

Thank you for your order.

This Agreement between Dr. Yukio Sasaki ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

Your confirmation email will contain your order number for future reference.

printable details

License Number: 4540140515320

License date: Mar 01, 2019

Licensed Content Publisher: Elsevier

Licensed Content Publication: Neuroscience Research

Licensed Content Title: Fragile X mental retardation protein regulates accumulation of the active zone protein Munc18-1 in presynapses via local translation in axons during synaptogenesis

Licensed Content Author: Shumaia Parvin, Renoma Takeda, Yu Sugiura, Makiko Neyazaki, Terukazu Nogi, Yukio Sasaki

Licensed Content Date: Available online 19 September 2018

Licensed Content Volume: n/a

Licensed Content Issue: n/a

Licensed Content Pages: 1

Type of Use: reuse in a journal/magazine

Requestor type: academic/educational institute

Portion: figures/tables/illustrations

Number of figures/tables/illustrations: 3

Format: electronic

Are you the author of this Elsevier article?: Yes

Will you be translating?: No

Original figure numbers: Fig. 1A, C, F, Fig. 4D, and Fig. 5C

Title of the article: Presynapse formation assay using presynapse organizer beads and “Neuron ball” culture

Publication new article is in: Journal of Visualized Experiments

Publisher of the new article: Other

Author of new article: Shumaia Parvin, Renoma Takeda, Yukio Sasaki

Expected publication date: Jul 2019

Estimated size of new article (number of pages): 8

Requestor Location: Dr. Yukio Sasaki

Yokohama City University

1-7-29 Suehiro-cho, Tsurumi-ward

Yokohama, Kanagawa 236-0004

Japan

Attn: Dr. Yukio Sasaki

Publisher Tax ID: JP00022

Total 0 JPY